Abstract
Approximately 7,770 new patients are diagnosed annually with breast cancer in Greece and 25% of them have human epidermal growth factor receptor 2 (HER2+) disease. 49% of newly diagnosed HER2+ patients have early-stage breast cancer (eBC). Based on a physician survey (N=95), 44% of patients receive neo-adjuvant treatment, of whom 33.7% have residual disease and require additional treatment in the adjuvant setting. The objective of this study was to evaluate the cost-effectiveness of trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ eBC after neoadjuvant taxane-based and HER2-targeted therapy, from the third-party payer perspective (EOPYY) in Greece.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
